[
    {
        "id": 0,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            0,
            1,
            2,
            3
        ],
        "_therapy": "Adcetris (brentuximab vedotin) in combination with doxorubicin, vinblastine, and dacarbazine"
    },
    {
        "id": 1,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            0
        ],
        "_therapy": "Adcetris (brentuximab vedotin)"
    },
    {
        "id": 2,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            4,
            5
        ],
        "_therapy": "Afinitor (everolimus) in combination with exemestane"
    },
    {
        "id": 3,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            6,
            7,
            8
        ],
        "_therapy": "Akeega (abiraterone acetate and niraparib)"
    },
    {
        "id": 4,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            9
        ],
        "_therapy": "Alecensa (alectinib)"
    },
    {
        "id": 5,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            10
        ],
        "_therapy": "Alunbrig (brigatinib)"
    },
    {
        "id": 6,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            11,
            12
        ],
        "_therapy": "Avastin (bevacizumab) in combination with erlotinib"
    },
    {
        "id": 7,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            13
        ],
        "_therapy": "Ayvakyt (avapritinib)"
    },
    {
        "id": 8,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            14
        ],
        "_therapy": "Besponsa (inotuzumab ozogamicin)"
    },
    {
        "id": 9,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            15
        ],
        "_therapy": "Blincyto (blinatumomab)"
    },
    {
        "id": 10,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            16
        ],
        "_therapy": "Bosulif (bosutinib)"
    },
    {
        "id": 11,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            17,
            18
        ],
        "_therapy": "Encorafenib and Binimetinib"
    },
    {
        "id": 12,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            19,
            18
        ],
        "_therapy": "Encorafenib and Cetuximab"
    },
    {
        "id": 13,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            17,
            18
        ],
        "_therapy": "Braftovi (encorafenib) in combination with binimetinib"
    },
    {
        "id": 14,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            20
        ],
        "_therapy": "Caprelsa (vandetanib)"
    },
    {
        "id": 15,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            21,
            22
        ],
        "_therapy": "Cobimetinib and vemurafenib"
    },
    {
        "id": 16,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            12,
            23
        ],
        "_therapy": "Cyramza (ramucirumab) and erlotinib"
    },
    {
        "id": 17,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            24,
            25
        ],
        "_therapy": "Taxotere (docetaxel)"
    },
    {
        "id": 18,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            26
        ],
        "_therapy": "Enhertu (trastuzumab deruxtecan)"
    },
    {
        "id": 19,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            19
        ],
        "_therapy": "Erbitux (cetuximab)"
    },
    {
        "id": 20,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            19,
            27
        ],
        "_therapy": "Erbitux (cetuximab) in combination with irinotecan"
    },
    {
        "id": 21,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            19,
            28,
            29
        ],
        "_therapy": "Erbitux (cetuximab) in combination with 5-fluorouracil and oxaliplatin"
    },
    {
        "id": 22,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            30
        ],
        "_therapy": "Faslodex (fulvestrant)"
    },
    {
        "id": 23,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            30,
            31
        ],
        "_therapy": "Faslodex (fulvestrant) in combination with palbociclib"
    },
    {
        "id": 24,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            32
        ],
        "_therapy": "Gavreto (pralsetinib)"
    },
    {
        "id": 25,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            33
        ],
        "_therapy": "Iressa (gefitinib)"
    },
    {
        "id": 26,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            34
        ],
        "_therapy": "Giotrif (afatinib)"
    },
    {
        "id": 27,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            25
        ],
        "_therapy": "Herceptin (trastuzumab)"
    },
    {
        "id": 28,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            35,
            25
        ],
        "_therapy": "Herceptin (trastuzumab)"
    },
    {
        "id": 29,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            24,
            25
        ],
        "_therapy": "Herceptin (trastuzumab)"
    },
    {
        "id": 30,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            36,
            25
        ],
        "_therapy": "Herceptin (trastuzumab) in combination with an aromatase inhibitor"
    },
    {
        "id": 31,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            35,
            25
        ],
        "_therapy": "Herceptin (trastuzumab) in combination with paclitaxel or docetaxel"
    },
    {
        "id": 32,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            24,
            25
        ],
        "_therapy": "Herceptin (trastuzumab) in combination with paclitaxel or docetaxel"
    },
    {
        "id": 33,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            24,
            25
        ],
        "_therapy": "Herceptin (trastuzumab) in combination with adjuvant chemotherapy containing docetaxel and carboplatin"
    },
    {
        "id": 34,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            2,
            25,
            35
        ],
        "_therapy": "Herceptin (trastuzumab) in combination with neoadjuvant chemotherapy"
    },
    {
        "id": 35,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            2,
            35,
            25
        ],
        "_therapy": "Herceptin (trastuzumab) in combination with neoadjuvant chemotherapy"
    },
    {
        "id": 36,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            38,
            39,
            25
        ],
        "_therapy": "Herceptin (trastuzumab) in combination with capecitabine or 5-fluorouracil and cisplatin"
    },
    {
        "id": 37,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            39,
            25,
            29
        ],
        "_therapy": "Herceptin (trastuzumab) in combination with capecitabine or 5-fluorouracil and cisplatin"
    },
    {
        "id": 38,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            40,
            31
        ],
        "_therapy": "Ibrance (palbociclib) in combination with an aromatase inhibitor"
    },
    {
        "id": 39,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            30,
            31
        ],
        "_therapy": "Ibrance (palbociclib) in combination with fulvestrant"
    },
    {
        "id": 40,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            41
        ],
        "_therapy": "Imatinib"
    },
    {
        "id": 41,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            42
        ],
        "_therapy": "Imatinib"
    },
    {
        "id": 42,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            43
        ],
        "_therapy": "Iclusig (ponatinib)"
    },
    {
        "id": 43,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            44
        ],
        "_therapy": "Imfinzi (durvalumab)"
    },
    {
        "id": 44,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            44,
            45
        ],
        "_therapy": "Imfinzi (durvalumab) in combination with tremelimumab and platinum-based chemotherapy."
    },
    {
        "id": 45,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            44,
            35
        ],
        "_therapy": "Imfinzi (durvalumab) in combination with carboplatin and paclitaxel followed by Imfinzi (durvalumab) as monotherapy."
    },
    {
        "id": 46,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            44,
            46,
            35
        ],
        "_therapy": "Imfinzi (durvalumab) in combination with carboplatin and paclitaxel followed by Imfinzi (durvalumab) in combination with olaparib."
    },
    {
        "id": 47,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            44,
            45
        ],
        "_therapy": "Imjudo (tremelimumab) in combination with durvalumab and platinum-based chemotherapy"
    },
    {
        "id": 48,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            47,
            35
        ],
        "_therapy": "Jemperli (dostarlimab) in combination with carboplatin and paclixtaxel"
    },
    {
        "id": 49,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            47
        ],
        "_therapy": "Jemperli (dostarlimab) in combination with carboplatin and paclixtaxel"
    },
    {
        "id": 50,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            48
        ],
        "_therapy": "Keytruda (pembrolizumab)"
    },
    {
        "id": 51,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            48,
            49
        ],
        "_therapy": "Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy"
    },
    {
        "id": 52,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            39,
            48,
            49
        ],
        "_therapy": "Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy"
    },
    {
        "id": 53,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            39,
            50,
            48
        ],
        "_therapy": "Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy"
    },
    {
        "id": 54,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            50,
            48
        ],
        "_therapy": "Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy"
    },
    {
        "id": 55,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            35,
            48
        ],
        "_therapy": "Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy"
    },
    {
        "id": 56,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            48,
            29
        ],
        "_therapy": "Keytruda (pembrolizumab)"
    },
    {
        "id": 57,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            39,
            48,
            29
        ],
        "_therapy": "Keytruda (pembrolizumab)"
    },
    {
        "id": 58,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            39,
            48,
            29
        ],
        "_therapy": "Keytruda (pembrolizumab) in combination with platinum and fluoropyrimidine-based chemotherapy"
    },
    {
        "id": 59,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            48,
            29
        ],
        "_therapy": "Keytruda (pembrolizumab) in combination with platinum and fluoropyrimidine-based chemotherapy"
    },
    {
        "id": 60,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            35,
            48
        ],
        "_therapy": "Keytruda (pembrolizumab) in combination with chemotherapy"
    },
    {
        "id": 61,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            51,
            48
        ],
        "_therapy": "Keytruda (pembrolizumab) in combination with chemotherapy"
    },
    {
        "id": 62,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            50,
            48
        ],
        "_therapy": "Keytruda (pembrolizumab) in combination with chemotherapy"
    },
    {
        "id": 63,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            35,
            48
        ],
        "_therapy": "Keytruda (pembrolizumab) in combination with chemotherapy with or without bevacizumab"
    },
    {
        "id": 64,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            11,
            37,
            35,
            48
        ],
        "_therapy": "Keytruda (pembrolizumab) in combination with chemotherapy with or without bevacizumab"
    },
    {
        "id": 65,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            39,
            48,
            25,
            29
        ],
        "_therapy": "Keytruda (pembrolizumab) in combination with trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy"
    },
    {
        "id": 66,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            48,
            25,
            29
        ],
        "_therapy": "Keytruda (pembrolizumab) in combination with trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy"
    },
    {
        "id": 67,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            39,
            48,
            29
        ],
        "_therapy": "Keytruda (pembrolizumab) in combination fluoropyrimidine and platinum -containing chemotherapy"
    },
    {
        "id": 68,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            48,
            29
        ],
        "_therapy": "Keytruda (pembrolizumab) in combination with fluoropyrimidine and platinum-containing chemotherapy"
    },
    {
        "id": 69,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            52
        ],
        "_therapy": "Kadcyla (trastuzumab emtansine)"
    },
    {
        "id": 70,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            40,
            53
        ],
        "_therapy": "Kisqali (ribociclib) in combination with an aromatase inhibitor or fulvestrant"
    },
    {
        "id": 71,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            30,
            53
        ],
        "_therapy": "Kisqali (ribociclib) in combination with an aromatase inhibitor or fulvestrant"
    },
    {
        "id": 72,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            54
        ],
        "_therapy": "Krazati (adagrasib)"
    },
    {
        "id": 73,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            55
        ],
        "_therapy": "Libtayo (cemiplimab)"
    },
    {
        "id": 74,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            55,
            49
        ],
        "_therapy": "Libtayo (cemiplimab) in combination with platinum-based chemotherapy"
    },
    {
        "id": 75,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            56
        ],
        "_therapy": "Lorviqua (lorlatinib)"
    },
    {
        "id": 76,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            57
        ],
        "_therapy": "Lumykras (sotorasib)"
    },
    {
        "id": 77,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            46
        ],
        "_therapy": "Lynparza (olaparib)"
    },
    {
        "id": 78,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            11,
            46
        ],
        "_therapy": "Lynparza (olaparib) in combination with bevacizumab"
    },
    {
        "id": 79,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            11,
            46
        ],
        "_therapy": "Lynparza (olaparib)"
    },
    {
        "id": 80,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            44,
            46
        ],
        "_therapy": "Lynparza (olaparib) in combination with durvalumab for maintence treatment, after not progressing on first-line treatment with durvalumab in combination with carboplatin and paclitaxel"
    },
    {
        "id": 81,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            58
        ],
        "_therapy": "Lytgobi (futibatinib)"
    },
    {
        "id": 82,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            59,
            60,
            2,
            8,
            61
        ],
        "_therapy": "MabThera (rituximab) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone)"
    },
    {
        "id": 83,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            59,
            62,
            63,
            2,
            64,
            65,
            60,
            61
        ],
        "_therapy": "MabThera (rituximab) in combination with chemotherapy"
    },
    {
        "id": 84,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            66
        ],
        "_therapy": "Mekinist (trametinib)"
    },
    {
        "id": 85,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            67,
            66
        ],
        "_therapy": "Mekinist (trametinib) in combination with dabrafenib"
    },
    {
        "id": 86,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            17,
            18
        ],
        "_therapy": "Mektovi (binimetinib) in combination with encorafenib"
    },
    {
        "id": 87,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            63,
            68,
            69
        ],
        "_therapy": "Mylotarg (gemtuzumab ozogamicin) in combination with daunorubicin (DNR) and cytarabine (AraC)"
    },
    {
        "id": 88,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            70
        ],
        "_therapy": "Nerlynx (neratinib)"
    },
    {
        "id": 89,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            71,
            72,
            49
        ],
        "_therapy": "Opdivo (nivolumab) in combination with ipilimumab and 2 cycles of platinum-based chemotherapy"
    },
    {
        "id": 90,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            39,
            71,
            72,
            49
        ],
        "_therapy": "Opdivo (nivolumab) in combination with ipilimumab and 2 cycles of platinum-based chemotherapy"
    },
    {
        "id": 91,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            71,
            72,
            35
        ],
        "_therapy": "Opdivo (nivolumab) in combination with ipilimumab and 2 cycles of platinum-based chemotherapy"
    },
    {
        "id": 92,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            72,
            35
        ],
        "_therapy": "Opdivo (nivolumab) in combination with platinum-based chemotherapy"
    },
    {
        "id": 93,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            72,
            49
        ],
        "_therapy": "Opdivo (nivolumab) in combination with platinum-based chemotherapy"
    },
    {
        "id": 94,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            39,
            50,
            72
        ],
        "_therapy": "Opdivo (nivolumab) in combination with platinum-based chemotherapy"
    },
    {
        "id": 95,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            72
        ],
        "_therapy": "Opdivo (nivolumab)"
    },
    {
        "id": 96,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            71,
            72
        ],
        "_therapy": "Opdivo (nivolumab) in combination with ipilimumab"
    },
    {
        "id": 97,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            39,
            72,
            29
        ],
        "_therapy": "Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-based combination chemotherapy"
    },
    {
        "id": 98,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            72,
            28,
            29
        ],
        "_therapy": "Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-based combination chemotherapy"
    },
    {
        "id": 99,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            72,
            28
        ],
        "_therapy": "Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-based combination chemotherapy"
    },
    {
        "id": 100,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            72,
            73
        ],
        "_therapy": "Opdualag (relatlimab / nivolumab)"
    },
    {
        "id": 101,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            74
        ],
        "_therapy": "Orserdu (elacestrant)"
    },
    {
        "id": 102,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            59,
            2,
            35,
            75,
            25
        ],
        "_therapy": "Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy"
    },
    {
        "id": 103,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            24,
            75,
            25
        ],
        "_therapy": "Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy"
    },
    {
        "id": 104,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            59,
            24,
            2,
            75,
            25,
            29
        ],
        "_therapy": "Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy"
    },
    {
        "id": 105,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            59,
            2,
            35,
            75,
            25,
            29
        ],
        "_therapy": "Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy"
    },
    {
        "id": 106,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            59,
            24,
            76,
            75,
            25
        ],
        "_therapy": "Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy"
    },
    {
        "id": 107,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            59,
            76,
            35,
            75,
            25
        ],
        "_therapy": "Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy"
    },
    {
        "id": 108,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            24,
            75,
            25
        ],
        "_therapy": "Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy"
    },
    {
        "id": 109,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            24,
            75,
            25
        ],
        "_therapy": "Perjeta (pertuzumab) in combination with trastuzumab and docetaxel"
    },
    {
        "id": 110,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            59,
            2,
            35,
            75,
            25
        ],
        "_therapy": "Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy"
    },
    {
        "id": 111,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            24,
            75,
            25
        ],
        "_therapy": "Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy"
    },
    {
        "id": 112,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            59,
            24,
            76,
            75,
            25,
            29
        ],
        "_therapy": "Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy"
    },
    {
        "id": 113,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            59,
            76,
            35,
            75,
            25,
            29
        ],
        "_therapy": "Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy"
    },
    {
        "id": 114,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            59,
            24,
            2,
            75,
            25,
            29
        ],
        "_therapy": "Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy"
    },
    {
        "id": 115,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            59,
            2,
            35,
            75,
            25,
            29
        ],
        "_therapy": "Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy"
    },
    {
        "id": 116,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            59,
            24,
            76,
            75,
            25
        ],
        "_therapy": "Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy"
    },
    {
        "id": 117,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            59,
            76,
            35,
            75,
            25
        ],
        "_therapy": "Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy"
    },
    {
        "id": 118,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            24,
            75,
            25
        ],
        "_therapy": "Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy"
    },
    {
        "id": 119,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            24,
            75,
            25
        ],
        "_therapy": "Phesgo (pertuzumab / trastuzumab) in combination with docetaxel"
    },
    {
        "id": 120,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            77,
            30
        ],
        "_therapy": "Piqray (alpelisib) in combination with fulvestrant"
    },
    {
        "id": 121,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            78
        ],
        "_therapy": "Retsevmo (selpercatinib)"
    },
    {
        "id": 122,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            79
        ],
        "_therapy": "Revlimid (lenalidomide)"
    },
    {
        "id": 123,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            80
        ],
        "_therapy": "Rozlytrek (entrectinib)"
    },
    {
        "id": 124,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            81
        ],
        "_therapy": "Rozlytrek (entrectinib)"
    },
    {
        "id": 125,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            63,
            68,
            82
        ],
        "_therapy": "Rydapt (midostaurin)"
    },
    {
        "id": 126,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            83
        ],
        "_therapy": "Scemblix (asciminib)"
    },
    {
        "id": 127,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            67,
            66
        ],
        "_therapy": "Spexotras (trametinib) in combination with dabrafenib"
    },
    {
        "id": 128,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            84
        ],
        "_therapy": "Sprycel (dasatinib [anhydrous])"
    },
    {
        "id": 129,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            84
        ],
        "_therapy": "Sprycel (dasatinib [anhydrous]) in combination with chemotherapy"
    },
    {
        "id": 130,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            85
        ],
        "_therapy": "Tabrecta (capmatinib)"
    },
    {
        "id": 131,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            67
        ],
        "_therapy": "Tafinlar (dabrafenib)"
    },
    {
        "id": 132,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            67,
            66
        ],
        "_therapy": "Tafinlar (dabrafenib)"
    },
    {
        "id": 133,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            86
        ],
        "_therapy": "Tagrisso (osimertinib)"
    },
    {
        "id": 134,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            39,
            86
        ],
        "_therapy": "Tagrisso (osimertinib) in combination with pemetrexed and platinum-based chemotherapy"
    },
    {
        "id": 135,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            86
        ],
        "_therapy": "Tagrisso (osimertinib) in combination with pemetrexed and platinum-based chemotherapy"
    },
    {
        "id": 136,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            87
        ],
        "_therapy": "Talzenna (talazoparib)"
    },
    {
        "id": 137,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            12
        ],
        "_therapy": "Tarceva (erlotinib)"
    },
    {
        "id": 138,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            88
        ],
        "_therapy": "Tasigna (nilotinib)"
    },
    {
        "id": 139,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            89
        ],
        "_therapy": "Tecentriq (atezolizumab)"
    },
    {
        "id": 140,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            89,
            11,
            37,
            35
        ],
        "_therapy": "Tecentriq (atezolizumab) in combination with bevacizumab, paclitaxel, and carboplatin"
    },
    {
        "id": 141,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            89,
            37,
            51
        ],
        "_therapy": "Tecentriq (atezolizumab) in combination with nab-paclitaxel and carboplatin"
    },
    {
        "id": 142,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            89,
            51
        ],
        "_therapy": "Tecentriq (atezolizumab) in combination with nab-paclitaxel"
    },
    {
        "id": 143,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            90
        ],
        "_therapy": "Tepmetko (tepotinib)"
    },
    {
        "id": 144,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            91,
            92
        ],
        "_therapy": "Tibsovo (ivosidenib) in combination with azacitidine"
    },
    {
        "id": 145,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            92
        ],
        "_therapy": "Tibsovo (ivosidenib)"
    },
    {
        "id": 146,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            44,
            49,
            45
        ],
        "_therapy": "Tremelimumab AstraZeneca (tremelimumab) in combination with durvalumab and platinum-based chemotherapy"
    },
    {
        "id": 147,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            39,
            44,
            49,
            45
        ],
        "_therapy": "Tremelimumab AstraZeneca (tremelimumab) in combination with durvalumab and platinum-based chemotherapy"
    },
    {
        "id": 148,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            39,
            44,
            50,
            45
        ],
        "_therapy": "Tremelimumab AstraZeneca (tremelimumab) in combination with durvalumab and platinum-based chemotherapy"
    },
    {
        "id": 149,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            44,
            50,
            45
        ],
        "_therapy": "Tremelimumab AstraZeneca (tremelimumab) in combination with durvalumab and platinum-based chemotherapy"
    },
    {
        "id": 150,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            44,
            51,
            45
        ],
        "_therapy": "Tremelimumab AstraZeneca (tremelimumab) in combination with durvalumab and platinum-based chemotherapy"
    },
    {
        "id": 151,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            93
        ],
        "_therapy": "Trisenox (arsenic trioxide)"
    },
    {
        "id": 152,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            94
        ],
        "_therapy": "Trodelvy (sacituzumab govitecan)"
    },
    {
        "id": 153,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            38,
            25,
            95
        ],
        "_therapy": "Tukysa (tucatinib) in combination with trastuzumab and capecitabine"
    },
    {
        "id": 154,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            38,
            96
        ],
        "_therapy": "Tyverb (lapatinib) in combination with capecitabine"
    },
    {
        "id": 155,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            96,
            25
        ],
        "_therapy": "Tyverb (lapatinib) in combination with trastuzumab and chemotherapy"
    },
    {
        "id": 156,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            96,
            40
        ],
        "_therapy": "Tyverb (lapatinib) in combination with an aromataste inhibitor"
    },
    {
        "id": 157,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            97,
            28,
            29
        ],
        "_therapy": "Vectibix (panitumumab)"
    },
    {
        "id": 158,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            97,
            27,
            29
        ],
        "_therapy": "Vectibix (panitumumab)"
    },
    {
        "id": 159,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            97
        ],
        "_therapy": "Vectibix (panitumumab)"
    },
    {
        "id": 160,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            98
        ],
        "_therapy": "Venclyxto (venetoclax)"
    },
    {
        "id": 161,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            99
        ],
        "_therapy": "Verzenios (abemaciclib) in combination with endocrine therapy"
    },
    {
        "id": 162,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            99,
            36
        ],
        "_therapy": "Verzenios (abemaciclib) in combination with endocrine therapy"
    },
    {
        "id": 163,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            99,
            40
        ],
        "_therapy": "Verzenios (abemaciclib) in combination with endocrine therapy"
    },
    {
        "id": 164,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            99,
            30
        ],
        "_therapy": "Verzenios (abemaciclib) in combination with endocrine therapy"
    },
    {
        "id": 165,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            100
        ],
        "_therapy": "Vitrakvi (larotrectinib)"
    },
    {
        "id": 166,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            101
        ],
        "_therapy": "Vizimpro (dacomitinib)"
    },
    {
        "id": 167,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            102
        ],
        "_therapy": "Xalkori (crizotinib)"
    },
    {
        "id": 168,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            103
        ],
        "_therapy": "Xalkori (crizotinib)"
    },
    {
        "id": 169,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            104
        ],
        "_therapy": "Xospata (gilteritinib)"
    },
    {
        "id": 170,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            71,
            72,
            49
        ],
        "_therapy": "Yervoy (ipilimumab) in combination with nivolumab and 2 cycles of platinum-based chemotherapy"
    },
    {
        "id": 171,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            39,
            71,
            72,
            49
        ],
        "_therapy": "Yervoy (ipilimumab) in combination with nivolumab and 2 cycles of platinum-based chemotherapy"
    },
    {
        "id": 172,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            71,
            72,
            35
        ],
        "_therapy": "Yervoy (ipilimumab) in combination with nivolumab and 2 cycles of platinum-based chemotherapy"
    },
    {
        "id": 173,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            71,
            72
        ],
        "_therapy": "Yervoy (ipilimumab) in combination with nivolumab"
    },
    {
        "id": 174,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            22
        ],
        "_therapy": "Zelboraf (vemurafenib)"
    },
    {
        "id": 175,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            105,
            60
        ],
        "_therapy": "Zydelig (idelalisib) in combination with rituximab"
    },
    {
        "id": 176,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            106
        ],
        "_therapy": "Zykadia (ceritinib)"
    },
    {
        "id": 177,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            49,
            107
        ],
        "_therapy": "Tevimbra (tislelizumab) in combination with pemetrexed and platinum-based chemotherapy"
    },
    {
        "id": 178,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            39,
            49,
            107
        ],
        "_therapy": "Tevimbra (tislelizumab) in combination with pemetrexed and platinum-based chemotherapy"
    },
    {
        "id": 179,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            49,
            108
        ],
        "_therapy": "Rybrevant (amivantamab) in combination with carboplatin and pemetrexed"
    },
    {
        "id": 180,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            108
        ],
        "_therapy": "Rybrevant (amivantamab)"
    },
    {
        "id": 181,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            109,
            30
        ],
        "_therapy": "Truqap (capivasertib) in combination with fulvestrant"
    },
    {
        "id": 182,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            110
        ],
        "_therapy": "Balversa (erdafitinib)"
    },
    {
        "id": 183,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            28,
            111,
            29
        ],
        "_therapy": "Vyloy, in combination with fluoropyrimidine- and platinum-containing chemotherapy"
    },
    {
        "id": 184,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            38,
            28,
            111
        ],
        "_therapy": "Vyloy, in combination with fluoropyrimidine- and platinum-containing chemotherapy"
    },
    {
        "id": 185,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            34
        ],
        "_therapy": "Afatinib"
    },
    {
        "id": 186,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            9
        ],
        "_therapy": "Alectinib"
    },
    {
        "id": 187,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            83
        ],
        "_therapy": "Asciminib"
    },
    {
        "id": 188,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            16
        ],
        "_therapy": "Bosutinib"
    },
    {
        "id": 189,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            10
        ],
        "_therapy": "Brigatinib"
    },
    {
        "id": 190,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            106
        ],
        "_therapy": "Ceritinib"
    },
    {
        "id": 191,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            21,
            22
        ],
        "_therapy": "Cobimetinib in combination with Vemurafenib"
    },
    {
        "id": 192,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            102
        ],
        "_therapy": "Crizotinib"
    },
    {
        "id": 193,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            67
        ],
        "_therapy": "Dabrafenib"
    },
    {
        "id": 194,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            101
        ],
        "_therapy": "Dacomitinib"
    },
    {
        "id": 195,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            81
        ],
        "_therapy": "Entrectinib"
    },
    {
        "id": 196,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            56
        ],
        "_therapy": "Lorlatinib"
    },
    {
        "id": 197,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            82,
            68,
            63
        ],
        "_therapy": "Midostaurin, DAUNOrubicin and Cytarabine"
    },
    {
        "id": 198,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            112
        ],
        "_therapy": "Neratinib"
    },
    {
        "id": 199,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            6,
            7,
            8
        ],
        "_therapy": "Niraparib and Abiraterone acetate and prednisoLONE"
    },
    {
        "id": 200,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            46,
            11
        ],
        "_therapy": "Olaparib in combination with bevacizumab"
    },
    {
        "id": 201,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            46
        ],
        "_therapy": "Olaparib"
    },
    {
        "id": 202,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            46
        ],
        "_therapy": "Olaparib in combination with bevacizumab"
    },
    {
        "id": 203,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            86
        ],
        "_therapy": "Osimertinib"
    },
    {
        "id": 204,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            43
        ],
        "_therapy": "Ponatinib"
    },
    {
        "id": 205,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            87
        ],
        "_therapy": "Talazoparib"
    },
    {
        "id": 206,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            66,
            67
        ],
        "_therapy": "Trametinib and Dabrafenib"
    },
    {
        "id": 207,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            22
        ],
        "_therapy": "Vemurafenib"
    },
    {
        "id": 208,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            98
        ],
        "_therapy": "Venetoclax"
    },
    {
        "id": 209,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            113
        ],
        "_therapy": "Zanubrutinib"
    },
    {
        "id": 210,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            114
        ],
        "_therapy": "Acalabrutinib"
    },
    {
        "id": 211,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            115
        ],
        "_therapy": "Ibrutinib"
    },
    {
        "id": 212,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            105,
            60
        ],
        "_therapy": "Idelalisib and RiTUXimab"
    },
    {
        "id": 213,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            72,
            71
        ],
        "_therapy": "Nivolumab 3mg/kg with Ipilimumab 1mg/kg"
    },
    {
        "id": 214,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            48
        ],
        "_therapy": "Pembrolizumab 200mg monotherapy"
    },
    {
        "id": 215,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            100
        ],
        "_therapy": "Larotrectinib"
    },
    {
        "id": 216,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            33
        ],
        "_therapy": "Gefitinib"
    },
    {
        "id": 217,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            12
        ],
        "_therapy": "Erlotinib"
    },
    {
        "id": 218,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            52
        ],
        "_therapy": "Trastuzumab Emtansine"
    },
    {
        "id": 219,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            40,
            31
        ],
        "_therapy": "Palbociclib in combination with an aromatase inhibitor"
    },
    {
        "id": 220,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            30,
            31
        ],
        "_therapy": "Palbociclib in combination with fulvestrant"
    },
    {
        "id": 221,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            40,
            53
        ],
        "_therapy": "Ribociclib in combination with an aromatase inhibitor"
    },
    {
        "id": 222,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            30,
            53
        ],
        "_therapy": "Ribociclib in combination with an aromatase inhibitor"
    },
    {
        "id": 223,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            14
        ],
        "_therapy": "Inotuzumab ozogamicin"
    },
    {
        "id": 224,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            15
        ],
        "_therapy": "blinatumomab"
    },
    {
        "id": 225,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            0,
            39,
            63,
            64
        ],
        "_therapy": "Brentuximab vedotin and ESHAP therapy"
    },
    {
        "id": 226,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            59,
            2,
            35,
            75,
            25
        ],
        "_therapy": "Pertuzumab and trastuzumab and chemotherapy"
    },
    {
        "id": 227,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            24,
            75,
            25
        ],
        "_therapy": "Pertuzumab and trastuzumab and chemotherapy"
    },
    {
        "id": 228,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            59,
            24,
            2,
            75,
            25,
            29
        ],
        "_therapy": "Pertuzumab and trastuzumab and chemotherapy"
    },
    {
        "id": 229,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            59,
            2,
            35,
            75,
            25,
            29
        ],
        "_therapy": "Pertuzumab and trastuzumab and chemotherapy"
    },
    {
        "id": 230,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            59,
            24,
            76,
            75,
            25
        ],
        "_therapy": "Pertuzumab and trastuzumab and chemotherapy"
    },
    {
        "id": 231,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            59,
            76,
            35,
            75,
            25
        ],
        "_therapy": "Pertuzumab and trastuzumab and chemotherapy"
    },
    {
        "id": 232,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            24,
            75,
            25
        ],
        "_therapy": "Pertuzumab and trastuzumab and chemotherapy"
    },
    {
        "id": 233,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            63,
            68,
            69
        ],
        "_therapy": "gemtuzumab ozogamicin in combination with daunorubicin and cytarabine"
    },
    {
        "id": 234,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            48,
            49
        ],
        "_therapy": "Pembrolizumab in combination with PEMEtrexed and CARBOplatin"
    },
    {
        "id": 235,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            39,
            48,
            49
        ],
        "_therapy": "Pembrolizumab in combination with PEMEtrexed and CISplatin"
    },
    {
        "id": 236,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            44
        ],
        "_therapy": "Durvalumab"
    },
    {
        "id": 237,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            89
        ],
        "_therapy": "Atezolizumab"
    },
    {
        "id": 238,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            52
        ],
        "_therapy": "Trastuzumab emtansine"
    },
    {
        "id": 239,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            48,
            29
        ],
        "_therapy": "Pembrolizumab in combination with carboplatin and 5-fluorouracil"
    },
    {
        "id": 240,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            39,
            48,
            29
        ],
        "_therapy": "Pembrolizumab in combination with cisplatin and 5-fluorouracil"
    },
    {
        "id": 241,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            71,
            72,
            35
        ],
        "_therapy": "Nivolumab in combination with ipilimumab, carboplatin, and paclitaxel"
    },
    {
        "id": 242,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            71,
            72,
            49
        ],
        "_therapy": "Nivolumab in combination with ipilimumab, carboplatin, and pemetrexed"
    },
    {
        "id": 243,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            39,
            71,
            72,
            49
        ],
        "_therapy": "Nivolumab in combination with ipilimumab, cisplatin, and pemetrexed"
    },
    {
        "id": 244,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            89,
            51
        ],
        "_therapy": "Atezolizumab in combination with nab-paclitaxel"
    },
    {
        "id": 245,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            35,
            75,
            25
        ],
        "_therapy": "Phesgo (pertuzumab / trastuzumab) in combination with paclitaxel and carboplatin"
    },
    {
        "id": 246,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            0
        ],
        "_therapy": "Brentuximab vedotin"
    },
    {
        "id": 247,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            0,
            37,
            64,
            116
        ],
        "_therapy": "Brentuximab vedotin and ICE therapy"
    },
    {
        "id": 248,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            39,
            48,
            29
        ],
        "_therapy": "Pembrolizumab 200mg in combination with cisplatin and 5-fluorouracil infusional therapy"
    },
    {
        "id": 249,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            39,
            72,
            29
        ],
        "_therapy": "Nivolumab 480 mg, cisplatin 80mg/m2 and 5-fluorouracil infusional therapy"
    },
    {
        "id": 250,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            28,
            48,
            29
        ],
        "_therapy": "Pembrolizumab and FOLFOX-6"
    },
    {
        "id": 251,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            15
        ],
        "_therapy": "Blinatumomab"
    },
    {
        "id": 252,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            35,
            75,
            25
        ],
        "_therapy": "Pertuzumab / trastuzumab (phesgo) in combination with paclitaxel"
    },
    {
        "id": 253,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            35,
            75,
            25
        ],
        "_therapy": "Pertuzumab and trastuzumab in combination with paclitaxel"
    },
    {
        "id": 254,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            24,
            75,
            25
        ],
        "_therapy": "Pertuzumab / trastuzumab (phesgo) in combination with docetaxel"
    },
    {
        "id": 255,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            24,
            75,
            25
        ],
        "_therapy": "Pertuzumab in combination with trastuzumab and docetaxel"
    },
    {
        "id": 256,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            117,
            75,
            25
        ],
        "_therapy": "Pertuzumab / trastuzumab (phesgo) in combination with vinorelbine"
    },
    {
        "id": 257,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            117,
            75,
            25
        ],
        "_therapy": "Pertuzumab in combination trastuzumab and vinorelbine"
    },
    {
        "id": 258,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            75,
            25
        ],
        "_therapy": "Pertuzumab / trastuzumab (phesgo)"
    },
    {
        "id": 259,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            24,
            75,
            25
        ],
        "_therapy": "docetaxel, carboplatin, trastuuzmab, and pertuzumab"
    },
    {
        "id": 260,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            72,
            35
        ],
        "_therapy": "Nivolumab 360mg and Chemotherapy"
    },
    {
        "id": 261,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            50,
            72
        ],
        "_therapy": "Nivolumab 360mg and Chemotherapy"
    },
    {
        "id": 262,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            39,
            50,
            72
        ],
        "_therapy": "Nivolumab 360mg and Chemotherapy"
    },
    {
        "id": 263,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            72,
            49
        ],
        "_therapy": "Nivolumab 360mg and Chemotherapy"
    },
    {
        "id": 264,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            39,
            72,
            49
        ],
        "_therapy": "Nivolumab 360mg and Chemotherapy"
    },
    {
        "id": 265,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            59,
            118,
            35,
            48
        ],
        "_therapy": "pembroliuzmab in combination with carboplatin and paclitaxel and doxorubicin and cyclophosphamide"
    },
    {
        "id": 266,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            25
        ],
        "_therapy": "Trastuzumab"
    },
    {
        "id": 267,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            11,
            35
        ],
        "_therapy": "Bevacizumab in combination with paclitaxel"
    },
    {
        "id": 268,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            11,
            12
        ],
        "_therapy": "Bevacizumab in combination with erlotinib"
    },
    {
        "id": 269,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            38
        ],
        "_therapy": "Capecitabine"
    },
    {
        "id": 270,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            38,
            96
        ],
        "_therapy": "Lapatinib in combination with Capecitabine"
    },
    {
        "id": 271,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            119
        ],
        "_therapy": "Tamoxifen"
    },
    {
        "id": 272,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            36
        ],
        "_therapy": "Anastrozole"
    },
    {
        "id": 273,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            24,
            25
        ],
        "_therapy": "Trastuzumab in combination with Docetaxel and Carboplatin"
    },
    {
        "id": 274,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            35,
            25
        ],
        "_therapy": "trastuzumab in combination with paclitaxel"
    },
    {
        "id": 275,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            24,
            25
        ],
        "_therapy": "Trastuzumab in combination with docetaxel"
    },
    {
        "id": 276,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            36,
            25
        ],
        "_therapy": "Trastuzumab in combination with an aromatase inhibitor"
    },
    {
        "id": 277,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            25
        ],
        "_therapy": "trastuzumab"
    },
    {
        "id": 278,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            35,
            25
        ],
        "_therapy": "trastuzumab in combination with paclitaxel or docetaxel"
    },
    {
        "id": 279,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            24,
            25
        ],
        "_therapy": "trastuzumab in combination with paclitaxel or docetaxel"
    },
    {
        "id": 280,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            24,
            25
        ],
        "_therapy": "trastuzumab in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin."
    },
    {
        "id": 281,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            2,
            35,
            25
        ],
        "_therapy": "neoadjuvant chemotherapy followed by adjuvant trastuzumab"
    },
    {
        "id": 282,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            4,
            5
        ],
        "_therapy": "Everolimus and Exemestane"
    },
    {
        "id": 283,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            59,
            2,
            35
        ],
        "_therapy": "Carboplatin and paclitaxel followed by doxorubicin cyclophosphamide"
    },
    {
        "id": 284,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            30
        ],
        "_therapy": "Fulvestrant"
    },
    {
        "id": 285,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            40
        ],
        "_therapy": "Letrozole"
    },
    {
        "id": 286,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            5
        ],
        "_therapy": "Exemestane"
    },
    {
        "id": 287,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            50
        ],
        "_therapy": "Gemcitabine and CARBOplatin (AUC2)"
    },
    {
        "id": 288,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            59,
            2,
            35,
            25
        ],
        "_therapy": "Doxorubicin, cyclophosphamide (AC 60/600) 21 day followed by weekly paclitaxel (80) and weekly trastuzumab therapy (ac-th)"
    },
    {
        "id": 289,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            35,
            25
        ],
        "_therapy": "paclitaxel (80) and trastuzumab therapy - 7 day (12 weeks)"
    },
    {
        "id": 290,
        "implication_type": "therapeutic sensitivity",
        "therapy": [

        ],
        "_therapy": "Abemaciclib in combination with endocrine therapy"
    },
    {
        "id": 291,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            75,
            25
        ],
        "_therapy": "Pertuzumab in combination with trastuzumab"
    },
    {
        "id": 292,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            24,
            75,
            25
        ],
        "_therapy": "DOCEtaxel, CARBOplatin, Trastuzumab (S/C) and Pertuzumab (TCH(S/C)P) Therapy"
    },
    {
        "id": 293,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            59,
            2,
            35
        ],
        "_therapy": "CARBOplatin (AUC 2) weekly and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin cycloPHOSphamide Therapy"
    },
    {
        "id": 294,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            35,
            75,
            25
        ],
        "_therapy": "pertuzumab, trastuzumab, paclitaxel, and carboplatin therapy (train-2)"
    },
    {
        "id": 295,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            24,
            75,
            25
        ],
        "_therapy": "DOCEtaxel, CARBOplatin and Pertuzumab/Trastuzumab (Phesgo)(TCHP) Therapy"
    },
    {
        "id": 296,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            59,
            2,
            35,
            48
        ],
        "_therapy": "Pembrolizumab (200mg), carboplatin AUC 5 and weekly paclitaxel 80mg/m^2 followed by doxorubicin and cyclophosphamide (ac 60/600) therapy."
    },
    {
        "id": 297,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            59,
            2,
            35,
            25
        ],
        "_therapy": "Dose Dense DOXOrubicin, cycloPHOSphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (DD AC-TH)"
    },
    {
        "id": 298,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            19
        ],
        "_therapy": "Cetuximab"
    },
    {
        "id": 299,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            97
        ],
        "_therapy": "Panitumumab"
    },
    {
        "id": 300,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            19,
            27,
            29
        ],
        "_therapy": "Cetuximab (7 days) and FOLFIRI (14 days) Therapy"
    },
    {
        "id": 301,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            19,
            27
        ],
        "_therapy": "Cetuximab (7 days) and Irinotecan (14 days) Therapy"
    },
    {
        "id": 302,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            28,
            97,
            29
        ],
        "_therapy": "Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy - 14 day"
    },
    {
        "id": 303,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            97,
            27,
            29
        ],
        "_therapy": "Panitumumab 6mg/kg and FOLFIRI Therapy-14 day"
    },
    {
        "id": 304,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            39,
            25,
            29
        ],
        "_therapy": "Trastuzumab 5-Fluorouracil and CISplatin Therapy - 21 days"
    },
    {
        "id": 305,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            19,
            27,
            29
        ],
        "_therapy": "Cetuximab (14 days) and FOLFIRI (14 days) Therapy"
    },
    {
        "id": 306,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            39,
            72,
            29
        ],
        "_therapy": "Nivolumab 240mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy"
    },
    {
        "id": 307,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            72,
            28,
            29
        ],
        "_therapy": "nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy (FOLFOX-6)"
    },
    {
        "id": 308,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            48
        ],
        "_therapy": "Pembrolizumab 400mg monotherapy"
    },
    {
        "id": 309,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            11,
            37,
            35,
            48
        ],
        "_therapy": "Pembrolizumab, PACLitaxel 175mg/m2, CARBOplatin AUC 5 and Bevacizumab Therapy"
    },
    {
        "id": 310,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            35,
            48
        ],
        "_therapy": "Pembrolizumab, PACLitaxel 175mg/m2 and CARBOplatin AUC 5 Therapy"
    },
    {
        "id": 311,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            105,
            120
        ],
        "_therapy": "Idelalisib and Ofatumumab Therapy"
    },
    {
        "id": 312,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            82
        ],
        "_therapy": "Midostaurin"
    },
    {
        "id": 313,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            39,
            50,
            72
        ],
        "_therapy": "Gemcitabine (1250mg/m2) and CISplatin (75mg/m2) Therapy - 21 day in combination with nivolumab"
    },
    {
        "id": 314,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            35,
            72
        ],
        "_therapy": "CARBOplatin (AUC 6) and PACLitaxel 200mg/m2 Therapy in combination with nivolumab"
    },
    {
        "id": 315,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            50,
            72
        ],
        "_therapy": "Gemcitabine (1000mg/m2) and Carboplatin (AUC 5) Therapy - 21 day in combination with nivolumab"
    },
    {
        "id": 316,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            39,
            49,
            72
        ],
        "_therapy": "Pemetrexed in combination with cisplatin and nivolumab"
    },
    {
        "id": 317,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            49,
            72
        ],
        "_therapy": "Pemetrexed in combination with carboplatin and nivolumab"
    },
    {
        "id": 318,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            59,
            60,
            2,
            8,
            61
        ],
        "_therapy": "(*riTUXimab) cycloPHOSphamide, DOXOrubicin, vinCRIStine and prednisoLONE (*R)-CHOP) Therapy"
    },
    {
        "id": 319,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            121,
            60
        ],
        "_therapy": "RiTUXimab and Bendamustine Therapy"
    },
    {
        "id": 320,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            39,
            63,
            60
        ],
        "_therapy": "(R*)-DHAP Therapy"
    },
    {
        "id": 321,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            59,
            2,
            64,
            122,
            60,
            61
        ],
        "_therapy": "Dose Adjusted riTUXimab, Etoposide, prednisoLONE, DOXOrubicin, cycloPHOSphamide and vinCRIStine (DA-R EPOCH) Therapy"
    },
    {
        "id": 322,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            64,
            116,
            60
        ],
        "_therapy": "(R*)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy"
    },
    {
        "id": 323,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            59,
            118,
            8,
            60,
            117
        ],
        "_therapy": "(*riTUXimab) cycloPHOSphamide, DOXOrubicin, vinCRIStine and prednisoLONE (*R)-CHOP Therapy - 14 day"
    },
    {
        "id": 324,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            59,
            118,
            8,
            60,
            117
        ],
        "_therapy": "(R*)-miniCHOP therapy - 21 days"
    },
    {
        "id": 325,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            50,
            28,
            60
        ],
        "_therapy": "R-Gemcitabine (1000mg/m2) Oxaliplatin Therapy - 14 day"
    },
    {
        "id": 326,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            59,
            64,
            122,
            60,
            61
        ],
        "_therapy": "R-CEOP"
    },
    {
        "id": 327,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            121,
            0
        ],
        "_therapy": "Brentuximab vedotin and Bendamustine Therapy"
    },
    {
        "id": 328,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            59,
            8,
            60,
            61
        ],
        "_therapy": "rituximab in combination with chemotherapy"
    },
    {
        "id": 329,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            59,
            2,
            8,
            60,
            61
        ],
        "_therapy": "rituximab in combination with chemotherapy"
    },
    {
        "id": 330,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            123,
            124,
            8,
            60
        ],
        "_therapy": "rituximab in combination with chemotherapy"
    },
    {
        "id": 331,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            59,
            2,
            64,
            125,
            8,
            60
        ],
        "_therapy": "rituximab in combination with chemotherapy"
    },
    {
        "id": 332,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            60
        ],
        "_therapy": "Rituximab"
    },
    {
        "id": 333,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            59,
            2,
            64,
            122,
            60,
            61
        ],
        "_therapy": "Dose Adjusted riTUXimab S/C, Etoposide, prednisoLONE, DOXOrubicin, cycloPHOSphamide and vinCRIStine"
    },
    {
        "id": 334,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            59,
            122,
            60,
            61
        ],
        "_therapy": "riTUXimab, Cyclophosphamide, vinCRIStine and prednisoLONE R-CVP Therapy"
    },
    {
        "id": 335,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            90
        ],
        "_therapy": "Tepotinib"
    },
    {
        "id": 336,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            26
        ],
        "_therapy": "Trastuzumab Deruxtecan (Enhertu)"
    },
    {
        "id": 337,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            37,
            59,
            2,
            35,
            48
        ],
        "_therapy": "Pembrolizumab in combination with chemotherapy (carboplatin and paclitaxel followed by doxorubicin and cyclophosphamide)"
    },
    {
        "id": 338,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            20
        ],
        "_therapy": "Vandetanib Therapy"
    },
    {
        "id": 339,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            93
        ],
        "_therapy": "Trentinoin (ATRA) with Arsenic Trioxide (ATO) Induction Therapy"
    },
    {
        "id": 340,
        "implication_type": "therapeutic sensitivity",
        "therapy": [
            94
        ],
        "_therapy": "sacituzumab govitecan"
    }
]